Citas bibligráficas
Tueros, F., (2020). Engineering Advanced Microbiome Therapeutics Using E. coli Nissle 1917 for Bile Acid and Neurodegenerative Related Disorders [Technical University of Denmark]. https://renati.sunedu.gob.pe/handle/sunedu/3157543
Tueros, F., Engineering Advanced Microbiome Therapeutics Using E. coli Nissle 1917 for Bile Acid and Neurodegenerative Related Disorders []. DK: Technical University of Denmark; 2020. https://renati.sunedu.gob.pe/handle/sunedu/3157543
@phdthesis{renati/3291,
title = "Engineering Advanced Microbiome Therapeutics Using E. coli Nissle 1917 for Bile Acid and Neurodegenerative Related Disorders",
author = "Tueros Farfán, Felipe Gonzalo",
publisher = "Technical University of Denmark",
year = "2020"
}
Advances in DNA synthesis, sequencing and a deeper understanding of biological and biochemical mechanisms have enabled the development of engineered microbes, and has expedited the speed at which they are constructed, tested and optimized. This has led to the revolution of biotechnology and its further application through different industrial fields. Even though this advancements have had significant repercussions regarding the discovery of new drugs and an increased efficiency in production capabilities derived from microbial fermentations, the medical sector has not benefited fully from the immense potential biotechnology has to offer. With the advent of microbiome research, diseases are being understood from a different perspective, taking into account the role that bacteria inhabiting our bodies have towards these events and how they modulate positively or negatively diseases. In this view, engineered microorganisms have the prospective to be much more than simple cell factories. Engineered probiotic strains, for example, could be targeted to address diseases on site, responding to the patient’s needs and to the environmental cues where they have stablished. This could prove to be a novel approach for treating chronic diseases, which often impair a normal life style, affecting deeply the life quality of patients. On the same line of thought, supporting amount of evidence is tilting the balance towards a more personalized treatment, as more insights into how drugs are absorbed, metabolized, regulated and degraded, are seen to depend greatly on the characteristics of each individual. Advanced microbiome therapeutics (AMT)s are envisioned to address the hurdles that modern medicine has come a crossed. These engineered microbes could potentially colonize the environment of choice, within the human body to deliver therapeutic action, by the production of specific drugs, degradation of toxic molecules or by modulating harmful microbial communities that pose a risk for normal wellbeing. Additionally, the development of such strains contributes dramatically to the transition into a more sustainable society, making us less dependent on natural resources for production capabilities, as these therapeutic microorganisms will produce the needed drugs by utilizing normal occurring resources in their given environments. This technology, however, is in its early stages and needs further research to properly assess its potential and fully understand its capabilities. In the present thesis, bile acid and neurodegenerative disorders are taken as examples for the engineering and development of advanced microbiome therapeutics. Envisioning them as possible approaches to address pathologies in these areas, enabling a more efficacious treatment approach. E. coli Nissle 1917, a well-documented probiotic, was employed as the bacterial chassis for such intended strains.
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
TuerosFarfanFG.pdf | Tesis | 2.16 MB | Adobe PDF | Visualizar/Abrir |
Autorizacion.pdf Acceso restringido | Autorización del registro | 266.15 kB | Adobe PDF | Visualizar/Abrir Solicita una copia |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons